Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
DVA 
DaVita HealthCare Partners Inc (DVA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/04/2025: DVA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $144.5
1 Year Target Price $144.5
| 1 | Strong Buy |
| 0 | Buy |
| 8 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 9.59% | Avg. Invested days 48 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 12/04/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 8.39B USD | Price to earnings Ratio 12.12 | 1Y Target Price 144.5 |
Price to earnings Ratio 12.12 | 1Y Target Price 144.5 | ||
Volume (30-day avg) 10 | Beta 0.99 | 52 Weeks Range 113.97 - 179.60 | Updated Date 12/5/2025 |
52 Weeks Range 113.97 - 179.60 | Updated Date 12/5/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 9.68 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 5.8% | Operating Margin (TTM) 14.83% |
Management Effectiveness
Return on Assets (TTM) 7.01% | Return on Equity (TTM) 61.62% |
Valuation
Trailing PE 12.12 | Forward PE 9.38 | Enterprise Value 20390296000 | Price to Sales(TTM) 0.63 |
Enterprise Value 20390296000 | Price to Sales(TTM) 0.63 | ||
Enterprise Value to Revenue 1.53 | Enterprise Value to EBITDA 7.69 | Shares Outstanding 70600000 | Shares Floating 37365756 |
Shares Outstanding 70600000 | Shares Floating 37365756 | ||
Percent Insiders 50.05 | Percent Institutions 51.73 |
Upturn AI SWOT
DaVita HealthCare Partners Inc
Company Overview
History and Background
DaVita Inc., formerly DaVita HealthCare Partners Inc., was founded in 1999. It evolved from a dialysis service provider into a major healthcare company focusing on kidney care and related services.
Core Business Areas
- Kidney Care: Provides dialysis services for patients with chronic kidney failure (CKF) and end-stage renal disease (ESRD). This includes in-center hemodialysis, home dialysis, and related laboratory services.
- DaVita Integrated Kidney Care (IKC): Offers integrated care models focused on improving outcomes and reducing costs for patients with kidney disease through comprehensive care management.
Leadership and Structure
DaVita's leadership team includes Javier Rodriguez (CEO). The organizational structure is based on its core business segments, with dedicated teams for kidney care and integrated care operations.
Top Products and Market Share
Key Offerings
- Dialysis Services: DaVita's primary service is dialysis, including hemodialysis and peritoneal dialysis, serving over 200,000 patients annually. Competitors include Fresenius Medical Care and US Renal Care. Market share data is included below in Market Dynamics.
- DaVita Integrated Kidney Care Programs: Focuses on preventative care and managing kidney disease progression, including chronic kidney disease education and care coordination. Competitors include Accountable Care Organizations (ACOs) and other integrated care providers. Revenue for this product is integrated with general care services.
Market Dynamics
Industry Overview
The kidney care industry is driven by the increasing prevalence of diabetes and hypertension, leading causes of kidney failure. The industry is highly regulated and reliant on government reimbursement programs.
Positioning
DaVita is one of the largest providers of dialysis services in the US, with a significant market share and a strong network of dialysis centers. Its competitive advantage lies in its scale, brand recognition, and integrated care model.
Total Addressable Market (TAM)
The global dialysis market is projected to reach around $105 billion by 2028. DaVita holds a sizable portion of this TAM, focusing primarily on the US market and leveraging its integrated care models to expand its reach.
Upturn SWOT Analysis
Strengths
- Large network of dialysis centers
- Strong brand recognition
- Integrated care model
- Established relationships with payers and providers
Weaknesses
- High reliance on government reimbursement
- Exposure to regulatory changes
- Potential for litigation related to dialysis treatment
- High debt levels
Opportunities
- Expanding integrated care services
- Growth in home dialysis market
- Strategic acquisitions and partnerships
- Technological advancements in dialysis treatment
Threats
- Changes in reimbursement policies
- Increased competition from other dialysis providers
- Rising operating costs
- Potential for negative publicity related to patient outcomes
Competitors and Market Share
Key Competitors
- FMS
- USREN
Competitive Landscape
DaVita and Fresenius Medical Care (FMS) dominate the US dialysis market. DaVita's competitive advantage lies in its integrated care model and patient outcomes.
Major Acquisitions
Reliant Medical Group
- Year: 2017
- Acquisition Price (USD millions): 400
- Strategic Rationale: Expanded DaVita's reach into physician practice management and value-based care.
Growth Trajectory and Initiatives
Historical Growth: DaVita's growth has been driven by organic expansion of its dialysis network and strategic acquisitions.
Future Projections: Future growth is expected to be driven by increasing prevalence of kidney disease, expansion of integrated care services, and growth in the home dialysis market.
Recent Initiatives: Recent initiatives include expanding its integrated care offerings, investing in technology to improve patient outcomes, and pursuing strategic partnerships.
Summary
DaVita is a leading provider of kidney care services with a strong market position and a focus on integrated care. While it benefits from the increasing prevalence of kidney disease, it faces regulatory risks and competition. Its expansion into integrated care and home dialysis presents growth opportunities, but managing costs and maintaining quality of care remain crucial.
Similar Stocks
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Reports
- Market Research Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data are estimates and may vary. Financial data is subject to change. Please consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About DaVita HealthCare Partners Inc
Exchange NYSE | Headquaters Denver, CO, United States | ||
IPO Launch date 1995-10-31 | CEO & Executive Director Mr. Javier J. Rodriguez | ||
Sector Healthcare | Industry Medical Care Facilities | Full time employees 76000 | Website https://www.davita.com |
Full time employees 76000 | Website https://www.davita.com | ||
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the provision of inpatient dialysis services and related laboratory services; and transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.